Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer

by Anne Marie McCarthy, Nitya Pradeep Kumar, Wei He, Susan Regan, Michaela Welch, Beverly Moy, A. John Iafrate, Andrew T. Chan, Aditya Bardia, Katrina Armstrong
Published 2020-04-01

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

by Laura M. Spring, Shealagh L. Clark, Tianyu Li, Shom Goel, Nabihah Tayob, Elene Viscosi, Elizabeth Abraham, Dejan Juric, Steven J. Isakoff, Erica Mayer, Beverly Moy, Jeffrey G. Supko, Sara M. Tolaney, Aditya Bardia
Published 2021-08-01

Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer

by David D. Yang, Daniela L. Buscariollo, Angel M. Cronin, Shicheng Weng, Melissa E. Hughes, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Stephen B. Edge, Beverly Moy, Joyce C. Niland, Antonio C. Wolff, Michael J. Hassett, Rinaa S. Punglia
Published 2020-08-01

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

by Stephen K. L. Chia, Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Janine Mansi, Carlos H. Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Sung-Bae Kim, Erik Hugger Jakobsen, Vernon Harvey, Nicholas Robert, John Smith, Graydon Harker, Bo Zhang, Lisa D. Eli, Yining Ye, Alshad S. Lalani, Marc Buyse, Arlene Chan
Published 2019-03-01